Aridis Pharma Founder & CEO Discusses Upcoming Milestones for its Late-Stage Pipeline

Aridis (OTC: ARDS) is revolutionizing how we treat infectious diseases through its unique technology platforms, which can quickly detect human-derived mAbs to treat infectious diseases. The Company's transformative approach utilizes a patient's own immune system to identify mAbs capable of fighting infections and underpins multiple late-stage programs. In January, Aridis announced positive top-line data from the first of two Phase 3 studies of its lead candidate, AR-301, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). In March, Aridis announced positive top-line data from its Phase 2a trial in cystic fibrosis, meeting primary and second endpoints for the study. Aridis received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 in May 2023 and is discussing results of its CF study with the FDA and the EMA to plan the definitive next steps. The Cystic Fibrosis Foundation is the largest shareholder of Aridis and has invested $12.5 million into the Company to date. Learn more at AridisPharmainfo.com. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Aridis Pharmaceuticals, Inc. (ARDS) is a client of RedChip Companies, Inc. ARDS agreed to pay RedChip Companies, Inc. a $8,000 monthly cash fee, beginning in February 26th, 2022 and 5000 restricted common shares of ARDS stock for 6 months of RedChip investor awareness services.   For full disclosure, visit RedChip.com/disclosures.